Need To Know
- Two months after the FDA approval of Rybrevant Faspro, clinicians are beginning to assess its real-world impact on workflow, patient experience, and delivery of EGFR/MET-targeted therapy.
- Early reactions show the subcutaneous formulation is addressing longstanding infusion challenges while maintaining the clinical efficacy established in the PALOMA-3 Study.
As practicing clinicians are beginning to appreciate, the emergence of subcutaneous EGFR-directed therapies in non–small cell lung cancer appears to be gaining real traction in the clinic—signaling a broader shift in how these agents may be delivered. The recent FDA approval of Rybrevant Faspro, a subcutaneous version of Rybrevant, represents a meaningful step in that evolution, offering a more time-efficient administration approach while maintaining clinical impact. By transitioning amivantamab from a prolonged intravenous infusion to a subcutaneous injection administered over minutes, the new formulation directly addresses one of the most significant logistical burdens associated with treatment: infusion time.
Dr. Farooqui works in community medicine at Ironwood Cancer & Research Centers in Chandler, Arizona and understand the unique set of challenges posed by doctors treating patients in their local communities. In many community settings, prolonged infusions can strain chair availability, increase nursing workload, and create scheduling bottlenecks that affect overall patient throughput.
For oncology practices, this approval has operational implications. Subcutaneous administration reduces infusion resource utilization, and staffing demands—factors that are increasingly critical in high-volume community and academic settings. It also decreases the likelihood and complexity of infusion-related reactions that require prolonged monitoring, improving clinic flow and patient throughput.
Importantly, the safety profile remains consistent with the known toxicities of amivantamab, including dermatologic events, diarrhea, edema, and thromboembolic risk. However, proactive management strategies—such as standardized skin care protocols and prophylactic anticoagulation in appropriate patients—have improved tolerability in routine practice.
From a patient-centered standpoint, minimizing time in the infusion suite enhances quality of life without compromising therapeutic intensity. For physicians, the approval signals not just a new formulation, but a practice-changing shift toward more efficient, experience-focused oncology care while maintaining the efficacy of a validated targeted therapy backbone.
Ultimately, Dr. Farooqui frames the shift as quality-of-life driven, saying, “those extra hours that they would normally be in the infusion room, they can be with their family… and almost take their mind off the cancer.”
“What’s really exciting to me is that I spent about a decade treating lung and head and neck cancers.
Dr. Roy S. Herbst, the chief of medical oncology at the Yale Cancer Center, Yale School of Medicine, previously told SurvivorNet that this cutting-edge medication offers a novel approach for a challenging subset of lung cancer known for its limited response to conventional therapies.
“Not every mutation is the same,” he says. “And now, depending on the mutation, we can have a specific drug so this is exciting.”
PALOMA-3 Findings
The FDA approval of Rybrevant Faspro follows data from the pivotal PALOMA-3 study, which helped establish subcutaneous amivantamab as a clinically viable alternative to the original intravenous formulation in EGFR-mutated non–small cell lung cancer.
PALOMA-3 was designed to evaluate whether subcutaneous delivery could maintain the efficacy of IV Rybrevant while improving tolerability and reducing administration burden. The study demonstrated comparable systemic exposure and antitumor activity, confirming that efficacy was preserved with the new formulation. Importantly, the safety profile was consistent with prior experience, with no new safety signals observed.
-
Objective response rates were similar between subcutaneous (≈30%) and intravenous (≈33%) arms, meeting noninferiority criteria.
-
Median progression-free survival favored the subcutaneous formulation (≈6.1 vs 4.3 months).
-
Overall survival was significantly improved with subcutaneous delivery (hazard ratio ~0.62), with higher 12-month survival rates.
-
Subcutaneous administration dramatically reduced infusion-related reactions (≈13% vs 66%) and shortened administration time (∼5 min vs 5 h).
-
Rates of venous thromboembolism were lower in the subcutaneous arm (≈9% vs 14%).
These results established that subcutaneous amivantamab offers comparable efficacy with a more favorable safety-tolerability and administration profile, forming the clinical basis for FDA approval.
